Demographic and clinical characteristics of the study population in the three WNV clinical groups and the two subgroups of WNVD
| Characteristic . | WNVIC n = 32a . | WNVF n = 61a . | WNVD n = 225a . | Subgroups of WNVD . | |
|---|---|---|---|---|---|
| Non-neuroinvasive WNVD n = 25a . | Neuroinvasive WNVD n = 200a . | ||||
| Age (years) | 54 [11] | 51 [14] | 68 [15] | 68 [12] | 68 [15] |
| Sex | | | | | |
| F | 5/32 (16%) | 27/61 (44%) | 75/225 (33%) | 8/25 (32%) | 67/200 (34%) |
| M | 27/32 (84%) | 33/61 (54%) | 147/225 (65%) | 17/25 (68%) | 130/200 (65%) |
| Unknown | 0/32 (0%) | 1/61 (2%) | 3/225 (1%) | 0/25 (0%) | 3/200 (1%) |
| Mortality | 0/32 (0%) | 0/61 (0%) | 23/225 (10%) | 0/25 (0%) | 23/200 (12%) |
| Unknown | 0/32 (0%) | 0/62 (0%) | 57/225 (25%) | 7/25 (28%) | 50/200 (25%) |
| Recruitment center | | | | | |
| Italy (PV) | 10/32 (31%) | 5/61 (8%) | 46/225 (20%) | 13/25 (52%) | 33/200 (17%) |
| Italy (MI) | 2/32 (6%) | 6/61 (10%) | 13/225 (6%) | 1/25 (4%) | 12/200 (6%) |
| Italy (BO) | 0/32 (0%) | 0/61 (0%) | 11/225 (5%) | 1/25 (4%) | 10/200 (5%) |
| USA | 0/32 (0%) | 15/61 (25%) | 24/225 (11%) | 0/25 (0%) | 24/200 (12%) |
| Austria | 17/32 (53%) | 27/61 (44%) | 31/225 (14%) | 5/25 (20%) | 26/200 (13%) |
| Israel | 3/32 (9%) | 2/61 (3%) | 32/225 (14%) | 4/25 (16%) | 28/200 (14%) |
| Hungary | 0/32 (0%) | 6/61 (10%) | 68/225 (30%) | 1/25 (4%) | 67/200 (34%) |
| Year of recruitment | | | | | |
| Before 2018 | 5/32 (16%) | 10/61 (16%) | 27/225 (12%) | 0/25 (0%) | 27/200 (14%) |
| 2018–2022 | 7/32 (22%) | 14/61 (23%) | 11/225 (5%) | 3/25 (12%) | 8/200 (4%) |
| 2023–2024 | 20/32 (63%) | 28/61 (46%) | 187/225 (83%) | 22/25 (88%) | 165/200 (83%) |
| Unknown | 0/32 (0%) | 9/76 (12%) | 0/225 (0%) | 0/25 (0%) | 0/200 (0%) |
| Characteristic . | WNVIC n = 32a . | WNVF n = 61a . | WNVD n = 225a . | Subgroups of WNVD . | |
|---|---|---|---|---|---|
| Non-neuroinvasive WNVD n = 25a . | Neuroinvasive WNVD n = 200a . | ||||
| Age (years) | 54 [11] | 51 [14] | 68 [15] | 68 [12] | 68 [15] |
| Sex | | | | | |
| F | 5/32 (16%) | 27/61 (44%) | 75/225 (33%) | 8/25 (32%) | 67/200 (34%) |
| M | 27/32 (84%) | 33/61 (54%) | 147/225 (65%) | 17/25 (68%) | 130/200 (65%) |
| Unknown | 0/32 (0%) | 1/61 (2%) | 3/225 (1%) | 0/25 (0%) | 3/200 (1%) |
| Mortality | 0/32 (0%) | 0/61 (0%) | 23/225 (10%) | 0/25 (0%) | 23/200 (12%) |
| Unknown | 0/32 (0%) | 0/62 (0%) | 57/225 (25%) | 7/25 (28%) | 50/200 (25%) |
| Recruitment center | | | | | |
| Italy (PV) | 10/32 (31%) | 5/61 (8%) | 46/225 (20%) | 13/25 (52%) | 33/200 (17%) |
| Italy (MI) | 2/32 (6%) | 6/61 (10%) | 13/225 (6%) | 1/25 (4%) | 12/200 (6%) |
| Italy (BO) | 0/32 (0%) | 0/61 (0%) | 11/225 (5%) | 1/25 (4%) | 10/200 (5%) |
| USA | 0/32 (0%) | 15/61 (25%) | 24/225 (11%) | 0/25 (0%) | 24/200 (12%) |
| Austria | 17/32 (53%) | 27/61 (44%) | 31/225 (14%) | 5/25 (20%) | 26/200 (13%) |
| Israel | 3/32 (9%) | 2/61 (3%) | 32/225 (14%) | 4/25 (16%) | 28/200 (14%) |
| Hungary | 0/32 (0%) | 6/61 (10%) | 68/225 (30%) | 1/25 (4%) | 67/200 (34%) |
| Year of recruitment | | | | | |
| Before 2018 | 5/32 (16%) | 10/61 (16%) | 27/225 (12%) | 0/25 (0%) | 27/200 (14%) |
| 2018–2022 | 7/32 (22%) | 14/61 (23%) | 11/225 (5%) | 3/25 (12%) | 8/200 (4%) |
| 2023–2024 | 20/32 (63%) | 28/61 (46%) | 187/225 (83%) | 22/25 (88%) | 165/200 (83%) |
| Unknown | 0/32 (0%) | 9/76 (12%) | 0/225 (0%) | 0/25 (0%) | 0/200 (0%) |
aMean [SD] or counts (frequency, %). PV, Pavia; MI, Milan; BO, Bologna.